Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma
Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of avastin combined with
gemcitabine, oxaliplatin, pegaspargase and dexamethasone(Avastin+ GemAOD) as first-line
treatment in patients with untreated natural killer(NK)/T cell lymphoma